Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of CC-90001 in idiopathic pulmonary fibrosis
2016-003473-17Phase 2Unknown
- Sponsor
- Celgene Corporation
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CC-90001 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Celgene Corporation. Primary endpoint: Forced vital capacity (percent predicted FVC difference). Status: unknown.
02
Drugs
CC-90001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2016-003473-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003473-17.